Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04854005 · ClinicalTrials.gov registry record

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

A clinical trial of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
78
Enrollment target
10
Study locations

NCT04854005: Active study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04854005 is a study of Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04854005, a study of Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
78 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to find out how often the researchers can avoid an ALND in patients with early-stage, node-positive HR+/HER2- breast cancer who are having upfront surgery. The study researchers think that, if AUS before surgery can help identify people who may have up to 3 affected lymph nodes, it will be possible to perform the less radical standard SLNB during surgery.

Primary Outcome

Completion ALND will be required if metastases are present in ≥3 SLNs on pathologic evaluation.

Conditions Studied

Interventions

  • PROCEDURE Breast surgery

Study Locations (10)

New York

  • Memorial Sloan Kettering Suffolk - Commack (Consent Only) - Commack
  • Memorial Sloan Kettering Westchester (Consent Only) - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (Consent Only) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Consent Only) - Montvale

Connecticut

  • Hartford Healthcare Cancer Alliance (Data collection only) - Hartford

Michigan

  • University of Michigan (Data Collection Only) - Ann Arbor

Pennsylvania

  • Lehigh Valley Health Network (Dara Collection Only) - Allentown

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2021-04-20
Est. Completion 2026-04
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04854005 still lists

NCT04854005 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Breast surgery is the first listed.

NCT04854005 lists 10 locations in 5 states (New York, New Jersey, Connecticut).

Frequently Asked Questions

What is clinical trial NCT04854005 about?

NCT04854005 is a clinical study titled "Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation". The purpose of this study is to find out how often the researchers can avoid an ALND in patients with early-stage, node-positive HR+/HER2- breast cancer who are having upfront surgery. The study researchers think that, if AUS before surgery can help identify people who may have up to 3 affected lymp...

What is the current status of trial NCT04854005?

This trial is currently active not recruiting. The enrollment target is 78 participants. The study started on 2021-04-20. Estimated completion is 2026-04.

What conditions does trial NCT04854005 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT04854005?

The interventions under investigation include: Breast surgery (PROCEDURE).

Who is sponsoring clinical trial NCT04854005?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04854005 being conducted?

This trial has 10 study locations across Connecticut, Michigan, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04854005's enrollment target sits among peer trials

78 662nd of 1224 higher than 556 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02397668 · 78 participants · NA

    CorMatrix Cor TRICUSPID ECM Valve Replacement Study

  • NCT03321656 · 78 participants · Phase 2

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

  • NCT03687814 · 78 participants · NA

    Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

  • NCT04018872 · 78 participants · Phase 2

    Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04854005, the US trial registry maintained by the National Library of Medicine. NCT04854005 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.